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Effects of vitamin D2 or D3 supplementation on glycaemic control
and cardiometabolic risk among people at risk of type 2 diabetes:
results of a randomized double-blind placebo-controlled trial
N. G. Forouhi1, R. K. Menon2, S. J. Sharp1, N. Mannan2, P. M. Timms3, A. R. Martineau2, A. P. Rickard1,
B. J. Boucher2, T. A. Chowdhury2,4, C. J. Griffiths2, S. E. Greenwald2, S. J. Griffin1 & G. A. Hitman2
1Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK
2Blizard Institute, Queen Mary University of London, London, UK
3Homerton University Hospital NHS Foundation Trust, London, UK
4Barts Healthcare NHS Trust, London, UK
Aims: To investigate the effect of short-term vitamin D supplementation on cardiometabolic outcomes among individuals with an elevated risk of
diabetes.
Methods: In a double-blind placebo-controlled randomized trial, 340 adults who had an elevated risk of type 2 diabetes (non-diabetic hyperglycaemia
or positive diabetes risk score) were randomized to either placebo, 100 000 IU vitamin D2 (ergocalciferol) or 100 000 IU vitamin D3 (cholecalciferol),
orally administered monthly for 4months. The primary outcome was change in glycated haemoglobin (HbA1c) between baseline and 4months, adjusted
for baseline. Secondary outcomes included: blood pressure; lipid levels; apolipoprotein levels; C-reactive protein levels; pulse wave velocity (PWV);
anthropometric measures; and safety of the supplementation.
Results: The mean [standard deviation (s.d.)] 25-hydroxyvitamin D [25(OH)D]2 concentration increased from 5.2 (4.1) to 53.9 (18.5) nmol/l in the D2
group, and the mean (s.d.) 25(OH)D3 concentration increased from 45.8 (22.6) to 83.8 (22.7) nmol/l in the D3 group. There was no effect of vitamin D
supplementation on HbA1c: D2 versus placebo: −0.05% [95% confidence interval (CI) −0.11, 0.02] or −0.51mmol/mol (95% CI −1.16, 0.14; p= 0.13); D3
versus placebo: 0.02% (95% CI −0.04, 0.08) or 0.19mmol/mol (95% CI −0.46, 0.83; p= 0.57). There were no clinically meaningful effects on secondary
outcomes, except PWV [D2 versus placebo: −0.68m/s (95% CI −1.31, −0.05); D3 versus placebo −0.73m/s (95% CI −1.42, −0.03)]. No important safety
issues were identified.
Conclusions: Short-term supplementation with vitamin D2 or D3 had no effect on HbA1c. The modest reduction in PWV with both D2 and D3 relative
to placebo suggests that vitamin D supplementation has a beneficial effect on arterial stiffness.
Keywords: intervention, placebo, pulse wave velocity, randomized, trial, type 2 diabetes, vitamin D2, vitamin D3
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Introduction
There is epidemiological evidence for an inverse association
between circulating 25-hydroxyvitamin D [25(OH)D] concen-
tration, an indicator of vitamin D status, and risk of type 2
diabetes; however, overall evidence from clinical trials does
not support a causal association for diabetes incidence [1] or
intermediate metabolic markers [2,3], although some clini-
cal trials have reported mixed findings [4,5]. Evidence for an
inverse association between circulating 25(OH)D concentra-
tions and cardiovascular outcomes has also been accumulat-
ing [6], but trial evidence does not clearly support a causal
effect for incident events or intermediate markers such as
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blood pressure, lipid levels, inflammation and arterial stiffness
[6–12].
Taken together, the current evidence remains inconclu-
sive, yet there is continued interest in the potential role of
vitamin D in cardiometabolic risk protection. Concurrently,
while many would consider vitamin D3 (cholecalciferol) more
effective than vitamin D2 (ergocalciferol) in maintaining
circulating concentrations of 25(OH)D [13,14], there is a
separate debate regarding bioavailability, with a higher pro-
portion of ‘free’ (i.e. unbound) or bioavailable 25(OH)D2
than free/bioavailable 25(OH)D3 in response to an equivalent
oral dose.
We conducted a trial to determine whether short-term oral
supplementation givenmonthly with vitamin D2 or vitamin D3
can lead to a reduction in glycaemia and an improvement in
cardiometabolic factors in people at risk of developing type 2
diabetes. We also examined the feasibility and safety of rela-
tively high dose vitamin D supplementation among individuals
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we drew from the general population without prior knowledge
of their circulating 25(OH)D concentrations.
Methods
Trial Design and Participants
We designed a double-blind, placebo-controlled randomized
clinical trial in people at risk of developing type 2 diabetes,
across two sites: East London and Cambridge, UK [15]. We
randomly allocated 340 participants to one of three groups
who received a monthly oral dose for 4months of 100 000 IU
(equivalent to 2.5mg) of either ergocalciferol (vitamin D2) or
cholecalciferol (vitamin D3) or a monthly oral dose of placebo.
Each participant was followed up for a total of 4months from
their first visit. The first three doses were given at the clinic
visit, while the final dose was taken at home after contact by
the study team, and their investigational medicinal products
(IMPs) consumption status was recorded (complete, partial or
failed). The two IMPs included ergocalciferol (Sterogyl, con-
taining 20 000 IU vitamin D2 per ml in ethanol) or cholecal-
ciferol (Vigantol oil, containing 20 000 IU vitamin D3 perml in
Miglyol® vehicle oil), representing a daily dose equivalent of
∼3300 IU. The placebo was Miglyol oil with esters of coconut
and palm-derived oils.
Details of the exclusion and inclusion criteria have been
described previously [15]. Men and women aged 30–75 years
registered with a general practitioner (London) or already
part of an ongoing observational study that was drawn from
lists of general practitioners (Cambridge), from any ethnic
group were eligible if they had an elevated risk of developing
type 2 diabetes, with either: (i) the presence of non-diabetic
hyperglycaemia defined by either impaired glucose tolerance
or impaired fasting glucose (World Health Organization cri-
teria), or glycated haemoglobin (HbA1c) levels of 5.5–6.49%
(37–47mmol/mol) or (ii) the presence of Cambridge Risk
Score thresholds that indicate elevated risk of diabetes [16].
Ethical approval for the trial was provided by the relevant
ethics committees and written informed consent was obtained
from all participants.
The trial was registered under the numbers: EudraCT
2009-011264-11; ISRCTN86515510.
Trial Outcomes
The primary efficacy outcome of the trial was a change in
the HbA1c concentration. There were multiple secondary car-
diometabolic outcomes, including systolic and diastolic blood
pressure, random cholesterol, HDL cholesterol, apolipoprotein
(Apo)A1 and ApoB, cardiovascular disease (CVD) risk score,
as assessed by the UK Prospective Diabetes Study (UKPDS)
risk engine (version 2) [17] and additionally in London only, a
measurement of arterial stiffness assessed by pulse wave veloc-
ity (PWV). Further secondary outcomes (both sites) included
anthropometry and serum concentrations of high-sensitivity
C-reactive protein (hsCRP), fructosamine and parathyroid hor-
mone (PTH). Other outcomes included the safety of oral vita-
min D without a pre-assessment of vitamin D status and
the feasibility and safety of the intervention [15]. For safety,
for all recruited participants at each trial visit, we recorded
point-of-care ionized calcium, laboratory serum-corrected cal-
cium and laboratory urinary calcium to creatinine ratio. Trial
participants who had an elevated point-of-care ionized calcium
level (>1.3mmol/l), an elevated urine calcium:creatinine ratio
(molar ratio >1) or an elevated serum corrected calcium level
(>2.65mmol/l) were excluded from further doses of the IMP,
but continued to be followed up. Provision was made for the
recording of adverse events or reactions.
Clinical and Laboratory Measurements
Systolic and diastolic blood pressure, weight, height and waist
circumference were measured according to standardized pro-
tocols. Body mass index was calculated as weight (kg) divided
by the square of height (m). PWV as a marker of arterial
stiffness was measured by a single operator detecting the
flow pulses in the carotid and femoral arteries in accordance
with recommended procedures [18] using handheld ultra-
sonic Doppler flow velocimeters (Dopplex MDII, Huntleigh
Healthcare, Cardiff, UK) driving pencil probes (4 and 8MHz)
placed over the carotid and femoral arteries, respectively. The
output from the velocimeters was passed to a custom-built
data acquisition system [19], sampling at a rate of 1 kHz, linked
to a computer which displayed the maximum velocity signals
from the two sites in real time. The mean PWV for at least
10–30 s of data, free of movement artifacts, was recorded for
each measurement session.
Baseline non-fasted blood samples were collected from all
participants during the first visit, to assess concentrations of
serum ionized calcium as well as serum 25(OH)D vitamin D,
HbA1c and other secondary biochemical endpoints. During
the second and third visits, blood samples were collected only
for safety analysis, and during the final (fourth) visit all blood
tests were repeated, as during the first visit. HbA1c samples
from the first and fourth visit were analysed immediately, while
aliquots for all other assays were stored frozen at −70 ∘C and
measured at the end of the trial.
We measured HbA1c levels according to International Fed-
eration of Clinical Chemistry and Laboratory Medicine stan-
dards in both trial centres and reported them additionally
in Diabetes Control and Complications Trial units. Serum
25(OH)D2 and D3 were measured using the liquid chro-
matography/tandem mass spectrometry method, with partic-
ipation in the VitaminD ExternalQuality Assessment Scheme
(DEQAS) quality assurance scheme.
Sample Size
Sample size calculations estimated that 207 participants (69 per
randomized group) were required to detect a 2.19mmol/mol
(0.2%) difference in mean HbA1c between the placebo and
either vitamin D2 or vitamin D3 groups with 90% power and
a 5% significance level, assuming a standard deviation (s.d.)
of HbA1c of 5.47mmol/mol (0.5%). To detect a 5-mmHg dif-
ference in mean systolic blood pressure between randomized
groups, assuming an s.d. of 16mmHg [15], yielded a require-
ment of 339 participants (113 in each group). Finally, to detect
a 0.5-m/s difference in PWV and assuming an s.d. of 1m/s
Volume 18 No. 4 April 2016 doi:10.1111/dom.12625 393
original article DIABETES, OBESITY AND METABOLISM
(S.E. Greenwald, unpublished observation), required 162 par-
ticipants (54 in each group).
Randomization and Blinding
Participants were randomized on a 1:1:1 basis within four
strata defined by age (30–50 or 51–75 years) and sex, with a
block size of six within each stratum. The order of treatments
within each block was determined by a computer-generated
pseudo-random sequence, generated by the IMPmanufacturer
(Nova Laboratories, Leicester, UK). Neither the participants,
investigators, nor the laboratory staff knew the treatment
allocation.
Statistical Analysis
The primary analysis of efficacy outcomes used an
intention-to-treat population, which included all partici-
pants in the group to which they were randomized, regardless
of the treatment actually received. A secondary analysis used a
per-protocol population, which excluded individuals who did
not take all doses of the IMP. The analysis of safety endpoints
used a safety population, which included all participants in
the group based on treatment actually received, thus it was
identical to the intention-to-treat population.
The baseline characteristics of the study population were
summarized separately within each randomized group using
means and s.d. values (continuous variables), medians and
interquartile ranges (skewed variables), or numbers and
percentages (categorical variables). Change in HbA1c from
baseline to 4months was compared separately between each
treatment group (D2 and D3) and placebo, using analysis of
covariance (ancova), with adjustment for baseline and centre.
To ensure that participants with missing baseline values for
the outcome could be included in the analysis, the missing
indicator method was used [20]. An analysis was performed
to check whether adjusting for age and sex (the randomiza-
tion stratifiers) in the ancova model had any impact on the
estimated treatment effects, with an a priori agreement not to
include them in the model if the impact was minimal.
For each of the secondary efficacy outcomes, differences
between each treatment group and placebo, together with
95% confidence intervals (CIs), were estimated using the same
method as that described for the primary outcome. Contin-
uous outcomes with skewed distributions [aspartate amino-
transferase (AST), hsCRP] were natural log transformed. To
enable the treatment differences for all efficacy outcomes to
be reported on the same scale, each estimated difference and
CI was divided by the s.d. of the relevant outcome at baseline.
The number and percentage of participants experiencing any
safety endpoints were reported within each randomized group.
For the primary endpoint, prespecified interactions between
treatment group and baseline HbA1c, and treatment group and
baseline 25(OH)Dwere tested by includingmultiplicative inter-
action terms in the ancova model. For the primary efficacy
endpoint only, an exploratory analysis was performed in which
a difference between the D2 and D3 groups was estimated using
ancova, as described above. All analyses were performed using
Stata 13 (Statacorp, College Station, TX, USA).
Results
The recruitment of participants for the trial and their follow-up
occurred between 2010 and 2012 and was continuous through-
out all seasons over the recruitment period. Of 340 participants,
114 were randomized to placebo, 112 to D2 and 114 to D3
(Figure 1). The distribution of baseline demographic, clinical
and biochemical characteristics was similar across the treat-
ment groups (Table 1). The percentages of participants who
took all four doses of their randomized medication were 80.7%
(placebo), 83.9% (D2) and 86.8% (D3; Figure 1).
The percentages of individuals with a 25(OH)D concentra-
tion <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the
placebo, D2 andD3 groups, respectively; at follow-up these per-
centages were 47.3, 4.5 and 3.5%. Mean (s.d.) 25(OH)D2 con-
centrations increased in the D2 group from 5.2 (4.1) nmol/l to
53.9 (18.5) nmol/l, and mean (s.d.) 25(OH)D3 concentrations
increased from 45.8 (22.6) nmol/l to 83.8 (22.7) nmol/l in the
D3 group. Between baseline and 4months there was no over-
all change in concentrations of 25(OH)D2, 25(OH)D3 and total
25(OH)D in the placebo group (Figure 2). In contrast, in the
D2 group, themean 25(OH)D2 concentration increased by 48.7
(19.2) nmol/l, while the 25(OH)D3 concentration decreased by
17.5 (22.1) nmol/l, and total 25(OH)D concentration increased
by 31.2 (28.6) nmol/l. In the D3 group there was no change
in mean 25(OH)D2 concentration, while 25(OH)D3 and total
25(OH)D concentrations increased by 38.3 (24.2) nmol/l and
38.1 (23.8) nmol/l, respectively.
Figure 3 shows that there was no evidence of a difference
between the placebo and vitamin D groups for the primary
outcome, HbA1c: the difference comparing D2 with placebo
was −0.05% (95% CI −0.11, 0.02) or −0.51 (95% CI −1.16,
0.14)mmol/mol (p= 0.13), and for D3 versus placebo it was
0.02% (95% CI −0.04%, 0.08%) or 0.19 (95% CI −0.46, 0.83)
mmol/mol (p= 0.57). Among the secondary outcomes, there
were no differences comparing D2 with placebo (Figure 4A)
or D3 with placebo (Figure 4B) for anthropometric measures,
blood pressure, hsCRP, CVD risk, assessed by UKPDS risk
engine, hepaticmarkers, or fructosamine. In theD2 group there
were small, but statistically significant, decreases from baseline
relative to placebo in total cholesterol andApoB (favouringD2),
as well as in HDL cholesterol and ApoA1 (favouring placebo;
Figure 4A). In the D3 group, there was a very small decrease
in ApoB concentration between baseline and follow-up relative
to placebo (Figure 4B). There was an increase in PTH in the
D2 group, but the difference between D2 and placebo was not
statistically significant (Figure 4A). There was a decrease in
PTH in the D3 group between baseline and follow-up that was
significantly different from the increase seen in the placebo
group (Figure 4B).Therewas a reduction frombaseline in PWV
in both the D2 [mean (s.d.) −0.17 (2.5)m/s] and D3 [mean
(s.d.) −0.75 (2.1)m/s] groups, relative to placebo [treatment
difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05)m/s; D3
vs placebo: −0.73 (95% CI −1.42, −0.03)m/s; Figure 4A, B]. In
the per-protocol population the findings were similar overall,
but of greater magnitude, in particular for PWV, for which the
treatment differenceswere−0.79 (95%CI−1.43,−0.14)m/s for
D2 versus placebo, and−1.01 (95%CI−1.69,−0.34)m/s for D3
versus placebo.
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Assessed for eligibility (n=74889)
Excluded/Not enrolled  (n=74549)
• Not meeting initial inclusion criteria 
check (n=67883)
• Not invited (943)
• Declined to participate or 
subsequently excluded before 
randomization (n=5723)
Placebo (n=114)
Doses received:
• 1: 114
• 2: 104
• 3: 86
• 4: 92
Vitamin D3 (n=114)
Doses received:
• 1: 114
• 2: 105
• 3: 101
• 4: 99
Baseline
Analysis
Follow-up
Randomized (n=340)
Enrollment
Vitamin D2 (n=112)
Doses received:
• 1: 112
• 2: 103
• 3: 96
• 4: 94
Withdrew from study (n=2)
Reasons:
• Requested (n= 1)
• Did not attend (n= 
1)
Discontinued study 
medication (n=20)
Reasons:
• Out of range 
blood/urine safety 
parameters (n= 17)
• Requested (n= 3)
Withdrew from study (n=10)
Reasons:
• Requested (n= 8)
• Did not attend (n= 2)
Discontinued study 
medication (n=8)
Reasons:
• Out of range 
blood/urine safety 
parameters (n= 6)
• Requested (n= 2)
Withdrew from study (n=4)
Reasons:
• Requested (n= 2)
• Did not attend (n= 2)
Discontinued study 
medication (n=11)
Reasons:
• Out of range 
blood/urine safety 
parameters (n= 8)
• Requested (n= 3)
Included in ITT analysis of 
primary endpoint (n=111)
Missing primary endpoint 
(n=3)
Included in ITT analysis of 
primary endpoint (n=100)
Missing primary endpoint 
(n=12)
Included in ITT analysis of 
primary endpoint (n=110)
Missing primary endpoint 
(n=4)
Figure 1. Flow diagram of participant recruitment into the vitamin D supplementation trial. ITT, intention to treat.
In the prespecified analyses, there was no evidence for inter-
action between treatment group and either baseline HbA1c
or baseline total 25(OH)D concentration on the primary out-
come (all p values between 0.15 and 0.74). In post hoc analyses
there was also no evidence of interaction between treatment
group and ethnicity (white vs. non-white ethnicity) or baseline
25(OH)D3 concentration (<50 vs.≥50 nmol/l). In the prespec-
ified exploratory analysis comparing HbA1c between D3 and
D2 groups, there was no evidence of a treatment effect [D3 vs
D2: 0.06% (95%CI−0.005, 0.13%) or 0.66 (95% CI−0.05, 1.38)
mmol/mol]. In a post hoc analysis there was also no evidence of
a difference in the change in fructosamine; D3 versus D2:−2.94
(95% CI −8.37, 2.48) μmol/l. There were no important safety
issues related to vitamin D supplementation (Table S1).
Discussion
Among individuals who are at elevated risk of future diabetes,
monthly supplementation for 4months with vitamin D2 and
vitamin D3 at a dose equivalent to 3300 IU/day was efficacious
in raising concentrations of 25(OH)D2 and 25(OH)D3, respec-
tively, but there were no differences between the placebo and
either of the vitamin D supplementation groups for the pri-
mary outcome of change in HbA1c concentration.. The null
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Table 1. Baseline demographic and clinical characteristics of participants by randomized group.
Placebo (N= 114) D2 (N= 112) D3 (N= 114)Total number of
missing values Mean (s.d.) or median (IQR) Mean (s.d.) or median (IQR) Mean (s.d.) or median (IQR)
Age, years 1 52.4 (8.5) 53.5 (8.7) 52.5 (8.2)
Body mass index, kg/m2 2 28.3 (5.0) 28.9 (5.5) 29.0 (5.5)
Systolic blood pressure, mm 0 127.9 (16.4) 126.9 (17.8) 128.6 (14.3)
Diastolic blood pressure, mm 0 77.6 (10.6) 75.8 (10.9) 77.6 (8.8)
Total 25(OH)D, nmol/l 1 51.1 (26.7) 53.8 (24.4) 51.2 (22.1)
25(OH)D2, nmol/l 1 5.2 (3.3) 5.2 (4.1) 5.4 (4.8)
25(OH)D3, nmol/l 1 45.8 (26.3) 48.6 (24.7) 45.8 (22.6)
HbA1c, % 2 5.9 (0.4) 5.9 (0.4) 5.9 (0.3)
HbA1c, mmol/mol 2 40.9 (3.8) 40.9 (4.2) 40.7 (3.4)
Total cholesterol, mmol/l 1 5.2 (1.1) 5.1 (0.9) 5.2 (0.9)
HDL cholesterol, mmol/l 1 1.3 (0.3) 1.3 (0.3) 1.3 (0.3)
Total/HDL ratio 1 4.3 (1.3) 4.0 (1.0) 4.2 (1.1)
Apolipoprotein A1, mmol/l 1 1.4 (0.3) 1.5 (0.2) 1.5 (0.3)
Apolipoprotein B, mmol/l 1 0.9 (0.2) 0.9 (0.2) 1.0 (0.2)
Modelled CVD risk, % 13 12.8 (9.4) 11.8 (8.3) 12.1 (8.2)
C-reactive protein, mg/l 1 1.5 (0.7, 3.2) 1.4 (0.7, 3.3) 2.0 (0.8, 4.3)
Fructosamine, μmol/l 1 236.2 (20.9) 240.1 (24.3) 237.2 (21.9)
Parathyroid hormone, pmol/l 2 5.1 (2.5) 5.2 (2.0) 5.3 (2.2)
Alkaline phosphatase, IU/l 1 72.7 (19.3) 74.3 (19.4) 74.1 (19.4)
Aspartate aminotransferase, IU/l 2 19.0 (17.0, 24.0) 19.0 (16.0, 22.0) 20.0 (17.0, 23.0)
Pulse wave velocity*, m/s 8 7.4 (2.0) 7.3 (2.7) 7.9 (2.0)
N (%) N (%) N (%)
Centre
Cambridge 58 (50.9) 56 (50.0) 58 (50.9)
London 56 (49.1) 56 (50.0) 56 (49.1)
Sex 0
Men 66 (57.9) 63 (56.3) 65 (57.0)
Women 48 (42.1) 49 (43.8) 49 (43.0)
Smoking 5
Never 49 (43.0) 54 (48.2) 51 (44.7)
Former 35 (30.7) 35 (31.3) 36 (31.6)
Current 28 (24.6) 21 (18.8) 26 (22.8)
Ethnic group 2
White 85 (74.6) 89 (79.5) 95 (83.3)
Non-white 27 (23.7) 23 (20.5) 19(16.7)
25(OH)D, serum 25-hydroxyvitamin D; CVD, cardiovascular disease; HbA1c, glycated haemoglobin.
*Pulse wave velocity was only measured at one centre (London), and includes 52, 55 and 53 participants in each treatment group, respectively.
effects of vitaminD supplementation onHbA1c, blood pressure
and inflammation in the present study suggest that vitamin D
supplementation is unlikely to have major benefit for diabetes
prevention or cardiometabolic risk. Nevertheless, the reduction
we observed in arterial stiffness, as assessed by PWV, is of inter-
est. The trial also showed the feasibility of relatively high dose
supplementation over 4months in a population unscreened for
baseline 25(OH)D concentrations.
The null findings for change in HbA1c are in keeping with
evidence from clinical trials appraised in two previous sys-
tematic reviews and meta-analyses [2,3]. Evidence from vita-
min D supplementation trials conducted subsequently to these
meta-analyses is also supportive of no significant effect on
HbA1c concentrations [4,10,21]. One trial did report a net
benefit, with 0.2% lower HbA1c concentration in the vitamin
D-supplemented group (n= 56) versus placebo (n= 53), but
this trial differed from other published work substantially, with
very-high-dose vitamin D3 supplementation (a mean dose of
∼88 000 IU/week, equivalent to >12 000 IU/day), longer dura-
tion of the intervention (for 1 year), and participants restricted
to those of Latino or African-American ethnicity, together
with presence of both impaired glucose regulation [HbA1c of
5.8–6.9% (40–52mmol/mol)], plus impaired fasting glucose
or impaired glucose tolerance, and hypovitaminosis-D defined
as 25(OH)D concentrations <75 nmol/l [5]. Notably, no other
marker of glycaemia or insulin resistance differed by treatment
group in that trial.
The null effect in the present study of supplementation on
several prespecified secondary outcomes is unsurprising in
light of the previous similar null reports for anthropometric
markers [8,21] and markers of cardiometabolic risk, including
blood pressure [8,10,22,23]C-reactive protein [8–10,24,25] and
liver enzymes [26], while our null finding for the UKPDS CVD
risk engine risk score is novel. Our observation of minor effects
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Figure 2. Mean [standard deviation (s.d.)] change in serum
25-hydroxyvitamin D [25(OH)D]2, 25(OH)D3 and total 25(OH)D
concentration (nmol/l) from baseline (BL) to 4months follow-up (FU),
by randomized group. Circles= 25(OH)D2; diamonds= 25(OH)D3;
squares= 25(OH)D.
on some lipid and Apo values is congruent with the past mixed
evidence for effects of vitamin D supplementation on lipids
[10,27]. A recent trial reported significantly reduced concen-
trations of ApoB in the vitamin D-supplemented group versus
placebo, but similarly to our findings, the small magnitude of
change was not considered clinically significant [28], while an
‘umbrella’ review of meta-analyses showed generally null find-
ings for lipid outcomes [29].
Our finding of a decrease in PWV between follow-up and
baseline in both the D2 and D3 groups relative to placebo is at
variance with the null findings for carotid-femoral PWV previ-
ously reported from a trial in 100 patients with diabetes, where
supplementation for 12weeks with 5000 IU/day of vitamin D3
versus placebo did not have an effect on brachial-ankle PWV
[12]. Other trials have reported conflicting findings in peo-
ple without diabetes [11,30–33]. Mechanisms underlying the
reduction in arterial stiffness by supplementation with both
vitamin D2 and D3 are unestablished, but possible pathways
include both direct and indirect effects on vascular cells, sup-
pression of the renin-angiotensin-aldosterone system, effects
on calcium metabolism leading to the calcification of arterial
elastin and the interplay of inflammation and oxidative stress
[23,31,34,35]. Our findings suggest that supplementation with
either vitamin D2 or D3 over a 4-month period could offer a
way to potentially favourably affect arterial stiffness, perhaps
by inhibition of matrix metalloproteinases [36,37], and should
stimulate further research to replicate these findings and to
understand the mechanisms of how 25(OH)D concentrations
may exert functional and structural alterations in the arterial
system.
While overall the total 25(OH)D concentrations were
increased in both D2 and D3 groups in the present trial,
the magnitude of increase in 25(OH)D was greater with D3
supplementation (mean increase of 38.3 nmol/) than with D2
supplementation (mean increase of 31.2 nmol/l), in keeping
with a previous meta-analysis comparing the effects of supple-
mentation with D2 or D3 [13] and with trials conducted since
then [14,38]. This may be partially attributable to the shorter
half-life of 25(OH)D2 versus 25(OH)D3 in the circulation,
which is related to the lower affinity of the D2 metabolite for
the vitamin D-binding protein [39]. It might also reflect our
finding that supplementation with vitamin D2 led to a decrease
in 25(OH)D3 concentrations, as also observed in non-trial
settings by others [40,41], while supplementation with vitamin
D3 did not affect 25(OH)D2 concentrations in the present trial.
The decrease in 25(OH)D3 concentrations in the D2 group
may suggest different bioavailability [38], possible more rapid
metabolism or clearance of circulating 25(OH)D3 following
D2 supplementation, or competition for enzymatic activity
D2 versus Placebo
D3 versus Placebo
Comparison
0.25 (2.2)
0.25 (2.2)
Placebo
-0.28 (2.6)
0.43 (2.6)
Active
Favours active  Favours placebo 
0-.2 -.1 .1 .2
Difference (95% CI) between active (vitamin D2 or D3) and placebo group (s.d. units)
Mean (s.d.) change from 
baseline (natural units)
Figure 3. Difference [95% confidence interval (CI)] in the primary outcome (HbA1c) between vitamin D2 and placebo and between vitamin D3 and
placebo groups, reported in units of baseline standard deviation (s.d.; 3.8mmol/mol). Mean (s.d.) change from baseline is presented in each group in the
natural units of the outcome (mmol/mol).
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BMI (kg/m2)
Waist (cm)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Total chol. (mmol/l)
HDL chol. (mmol/l)
Total/HDL chol.
ApoA1 (mmol/l)
ApoB (mmol/l)
ApoA1/ApoB (%)
CVD risk (UKPDS) (%)
Fruct. (µmol/l)
Corr. fruct. (µmol/l)
PTH (pmol/l)
ALP (IU/l)
ln-AST (ln IU/l)
ln-hsCRP (ln mg/l)
PWV (m/s)
Outcome
0.06 (0.7)   0.09 (1.1)
-0.78 (11.1)
-2.11 (7.3)  -1.85 (7.8)
0.02 (0.6)  -0.16 (0.6)
0.01 (0.2)  -0.05 (0.2)
-0.01 (0.5)  0.06 (0.4)
0.04 (0.1)   -0.04 (0.1)
0.01 (0.1)   -0.03 (0.1)
2.11 (32.8)  3.99 (27.6)
-0.04 (2.2)   -0.06 (3.2)
-0.81 (17.8)  -1.70 (18.3)
-1.47 (27.3)  -0.97 (25.8)
0.83 (1.9) 0.36 (1.8)
-1.11 (8.4) 0.24 (9.6)
-0.05 (0.2) -0.04 (0.3)
0.07 (1.3) 0.08 (1.2)
0.36 (1.7) -0.17 (2.5)
-0.57 (4.3)  0.16 (3.2)
  -1.61 (11.4)
Favours D2 Favours placebo
0-.8 -.6 -.4 -.2 .2 .4
Mean (s.d.) change from
baseline (natural units)
Placebo    D2 
Outcome
Mean (s.d.) change from
baseline (natural units)
Placebo      D3
Difference (95% CI) between vitamin D2 and placebo group (SD units)
Favours D2 Favours placebo
0-.8 -.6 -.4 -.2 .2 .4
Difference (95% CI) between vitamin D3 and placebo group (SD units)
BMI (kg/m2)
Waist (cm)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Total chol. (mmol/l)
HDL chol. (mmol/l)
Total/HDL chol.
ApoA1 (mmol/l)
ApoB (mmol/l)
ApoA1/ApoB (%)
CVD risk (UKPDS) (%)
Fruct. (µmol/l)
Corr. fruct. (µmol/l)
PTH (pmol/l)
ALP (IU/l)
ln-AST (ln IU/l)
ln-hsCRP (ln mg/l)
PWV (m/s)
0.06 (0.7) 0.47 (4.9)
-0.57 (4.3) -0.28 (5.8)
-0.78 (11.1)  -1.68 (10.9)
-2.11 (7.3)   -2.15 (7.3)
0.02 (0.6)   -0.11 (0.7)
0.01 (0.2)   -0.02 (0.2)
-0.01 (0.5)  -0.07 (0.5)
0.04 (0.1)  -0.01 (0.2)
0.01 (0.1)  -0.04 (0.1)
2.11 (32.8)  4.90 (26.1)
-0.04 (2.2)  -0.20 (2.1)
-0.81 (17.8)  -4.08 (24.1)
-1.47 (27.3)  -4.32 (30.7)
0.83 (1.9)  -0.49 (1.7)
-1.11 (8.4)  -1.41 (9.2)
-0.05 (0.2)  -0.02 (0.2)
0.07 (1.3)  -0.05 (1.1)
0.36 (1.7)  -0.75 (2.1)
Figure 4. Difference [95% confidence interval (CI)] in secondary outcomes between D2 (A) and D3 (B) and placebo group, reported in units of baseline
standard deviation (s.d.), alongside mean (s.d.) change from baseline in each group in the natural units of the outcome. BMI, body mass index; BP, blood
pressure; chol., cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; fruct., fructoasmine; corr. fruct., corrected fructosamine; ALP, alkaline
phosphatase; AST, aspartame transaminase; CVD, cardiovascular disease; UKPDS, United Kingdom Prospective Diabetes Study; hsCRP, high-sensitivity
C-reactive protein; PTH, parathyroid hormone; PWV, pulse wave velocity.
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by CYP2R1 for 25-hydroxylation of vitamin D2 and D3 [41].
It has been suggested that an upregulation in mechanisms
required to metabolize D2 and its metabolites may increase the
degradation of circulating 25(OH)D3 concentrations [42] but
the biological significance of these changes is currently unclear.
The strengths of the present trial include the cohort of
adults from different ethnic groups, of varying ages and both
sexes, and the use of a relatively high dose of vitamin D
supplementation at the daily equivalent dose of 3300 IU per day
that was effective in raising 25(OH)D concentrations.The com-
parison of both vitamin D3 and vitamin D2 against placebo for
cardiometabolic outcomes is novel. Our inclusion of several rel-
evant secondary endpoints and the assessment of the feasibility
and safety of 25(OH)D in relatively high doses givenmonthly in
a general population unscreened for 25(OH)D concentrations,
with high degree of participant retention, increases generaliz-
ability in clinical practice. Enrolling participants irrespective of
baseline vitamin D status was intentional to enable feasibility of
a ‘real-life’ trial that would not require pre-recruitment assess-
ment, and our examination of any differential effects by baseline
25(OH)D concentration in interaction analyses highlighted no
benefits in those with hypovitaminosis D.
The limitations of the present study included the inability
to draw conclusions for longer-term effects of supplementa-
tion beyond 4months. For the primary glycaemic endpoint of
HbA1c, this period could be considered short, but our null find-
ings for this outcome were supported by similar null findings
for fructosamine concentrations, yet we observed bioactivity
for PWV, lipid parameters and PTH. The study did not allow
us to compare D2 with D3 supplementation directly because
of sample size constraints, but an exploratory analysis was
null. The PWV findings are interesting but we acknowledge
the potential limitations of using surrogate markers of CVD.
Finally, the present study did not address whether different out-
comes would have been obtained with a daily compared with a
monthly regime.
In summary, short-term supplementation with vitamin D2
and D3 raised concentrations of 25(OH)D2 and 25(OH)D3,
respectively, but had no effect on HbA1c during the study
period. The modest reduction in PWV with both D2 and D3
versus placebo is suggestive of a beneficial effect of vitamin D
supplementation on arterial stiffness, and the clinical implica-
tions of this finding merit further investigation.
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